Merck + Co., Inc.

Other

A Brian Jones

Alan D Adams

Kun Liu

James Francis Dropinski

Derek J Von Langen

John J Acton, Iii

Joel Peter Berger

Clare E Gutteridge

Gaochao Zhou

Alexander Elbrecht

Guo-Qiang Shi

Karen Lamb MacNaul

Richard L Tolman

William H Parsons

Peter J Sinclair

Sheo B Singh

Yuan Cheng

Gregory John Hollingworth

Matthew John Lindon

Bruno Tse

John G Ondeyka

Victoria K Lombardo

Jeffrey Donald Hermes

Shaei Y Huang

Lauren Rogers

Ahren I Green

Aileen Bouffard

Weiguo Lui

Ali Shiafee

Libo Xu

Rebecca Elizabeth Brown

Victoria Alexandra Doughty

Christopher Richard Moyes

A class of 2-aryloxy-2-arylalkanoic acids comprises compounds that are potent agonists of PPAR alpha and/or gamma, and are therefore useful in the treatment, control or prevention of non-insulin dependent diabetes mellitus (NIDDM), hyperglycemia, dyslipidemia, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, atherosclerosis, obesity, vascular restenosis, inflammation, and other PPAR alpha and/or gamma mediated diseases, disorders and conditions.

2-aryloxy-2-arylalkanoic acids for diabetes and lipid disorders

The present invention provides compounds of formula (I); pharmaceutically acceptable salts and N-oxides thereof in which A, B, D and E are C or N with the proviso that one or more are N, R, R, R, R, Rand Rare simple substituents, n is 0-3 and y is an aryl, heteroaryl, carbocyclyl or fused-carbocyclyl group; as VR-1 antagonists for treating conditions or diseases in which pain and/or inflammation predominates; the use of the same for manufacturing medicaments, pharmaceutical compositions comprising them and methods of treatment utilizing them 

Heteroaromatic urea derivatives as VR-1 receptor modulators for treating pain

The present invention relates to novel LXR ligands of Formula I and the pharmaceutically acceptable salts, esters and tautomers thereof, which are useful in the treatment of dyslipidemic conditions, particularly depressed levels of HDL cholesterol. 

Therapeutic compounds for treating dyslipidemic conditions

Compounds of Formula Iand the pharmaceutically acceptable salts and esters thereof, wherein Z is selected from the group consisting of:

A class of acyl sulfamides comprises compounds that are potent ligands for PPAR gamma and generally have antagonist or partial agonist activity. The compounds may be useful in the treatment, control or prevention of obesity, non-insulin dependent diabetes mellitus (NIDDM), hyperglycemia, dyslipidemia, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, atherosclerosis, vascular restenosis, inflammation, and other PPAR gamma mediated diseases, disorders and conditions.

Acyl sulfamides for treatment of obesity, diabetes and lipid disorders

A class of aryloxyacetic acids comprises compounds that are potent agonists of PPAR alpha and/or gamma, and are therefore useful in the treatment, control or prevention of non-insulin dependent diabetes mellitus (NIDDM), hyperglycemia, dyslipidemia, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, atherosclerosis, obesity, vascular restenosis, inflammation, and other PPAR alpha and/or gamma mediated diseases, disorders and conditions.

Aryloxyacetic acids for diabetes and lipid disorders

Compounds of the formula ##STR1## are inhibitors of peptide binding to major histocompatibility complex type II proteins and may be used in the treatment and prevention of autoimmune diseases including: rheumatoid arthritis, Type I diabetes, multiple sclerosis, lupus erythematosis, Graves disease and pemphigus. The present invention also provides novel compositions, methods of treatment employing compounds of the present invention and methods of manufacture of the compounds of structural formula (I).

Inhibitors of peptide binding to MHC class II proteins

Compounds of the formula ##STR1## are inhibitors of peptide binding to major histocompatibility complex type II proteins and are useful in the treatment and prevention of autoimmune diseases including: rheumatoid arthritis, Type I diabetes, multiple sclerosis, lupus erythematosis, Graves disease and pemphigus. The present invention also provides novel compositions, methods of treatment employing the compounds of the present invention and methods of manufacture of the compounds of structural formula (I).

Inhibitors of peptide binding to MHO class II proteins

Pseudopeptide lactam inhibitors of peptide binding to MHC class II

Growing community of inventors

Clavering, United Kingdom

A Brian Jones